Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)

BTIG Affirms Kite Pharma (KITE) at 'Neutral' as ZUMA-6 Begins

October 6, 2016 11:45 AM EDT

BTIG affirms Kite Pharma, Inc. (Nasdaq: KITE) with a Neutral rating after the company announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentechs anti-PD-L1 cancer immunotherapy.

Analyst Dane Leone commented today: The... More

Stifel Reiterates Bullish View on Kite Pharma (KITE) Following New Trial News

October 6, 2016 10:12 AM EDT

Stifel analyst Thomas Shrader reiterated a Buy rating and $74 price target on Kite Pharma (NASDAQ: KITE) after the company announced this morning a new trial combining KTE-019 with Genentechs anti-PD-L1 antibody atezolizumab.

Shrader commented, "This cost-shared trial will explore using an... More